Research elucidating the pathogenesis of systemic lupus erythematosus (SLE) has defined
two critical families of mediators, type I interferon (IFN-I) and autoantibodies targeting nucleic …

Systemic lupus erythematosus (SLE) is a complex systemic autoimmune disease associated
with multiple immunologic abnormalities. Prominent among these is upregulation of type I …

Interferon alpha (IFN-α) is a critical mediator of human systemic lupus erythematosus (SLE).
This review will summarize evidence supporting the role for IFN-α in the initiation of human …

The aetiology of systemic lupus erythematosus (SLE) is multifactorial, and includes
contributions from the environment, stochastic factors, and genetic susceptibility. Great gains …

The discovery that type I interferon (IFN)-inducible genes were strongly upregulated in
peripheral blood in SLE over a decade ago sparked interest in understanding the …

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease affecting multiple
organs. A complex interaction of genetics, environment, and hormones leads to immune …

Current therapies for systemic lupus erythematosus (SLE), a debilitating, potentially lethal,
multifactorial systemic autoimmune disease, are limited to suppressing disease activity and …

Systemic lupus erythematosus (SLE) is a prototypic multisystem autoimmune disorder where
interplay of environmental and genetic risk factors leads to progressive loss of tolerance to …

Although the role of adaptive immune mechanisms, eg autoantibody formation and
abnormal T-cell activation, has been long noted in the pathogenesis of human systemic …

Autoreactive B cells and interferons are central players in systemic lupus erythematosus
(SLE) pathogenesis. The partial success of drugs targeting these pathways, however …